<DOC>
	<DOCNO>NCT03006172</DOCNO>
	<brief_summary>This open-label , multicenter , Phase I study design evaluate safety , tolerability , pharmacokinetics GDC-0077 administer orally single agent participant locally advance metastatic Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha ( PIK3CA ) -mutant solid tumor , include breast cancer , combination standard-of-care endocrine target therapy treatment locally advance metastatic PIK3CA-mutant hormone receptor-positive ( HR+ ) /human epidermal growth factor receptor 2 negative ( HER2- ) breast cancer . Participants enrol two stage : dose-escalation stage ( Stage I ) expansion stage ( Stage II ) . Participants assign one four regimen : GDC-0077 single agent ( Arm A ) , GDC-0077 combination palbociclib letrozole ( Arm B ) , GDC-0077 combination letrozole ( Arm C ) , GDC-0077 combination fulvestrant ( Arm D ) .</brief_summary>
	<brief_title>To Evaluate Safety , Tolerability , Pharmacokinetics GDC-0077 Single Agent Participants With Solid Tumors Combination With Endocrine Targeted Therapies Participants With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Evaluable measurable disease per RECIST , Version 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy great equal ( ≥ ) 12 week Adequate hematologic organ function , include blood count , liver kidney function Stage I Arm A ( GDC0077 ) : Locally advance , recurrent , metastatic , PIK3CA mutant , incurable solid tumor malignancy , include breast cancer Stages I II , Arm B : Postmenopausal female participant histologically document locally advanced metastatic PIK3CAmutant HR+/HER2 breast cancer Absolute neutrophil count ≥ 1500 per microliter Stages I II , Arm C Stage II Arm D : Postmenopausal female participant locally advance metastatic PIK3CAmutant HR+/HER2− breast cancer Stages I II : All participant must provide tumor tissue primary metastatic tumor site obtain prior new biopsy surgical procedure detection PIK3CA mutation central laboratory test . Confirmation adequate tissue require prior enrollment . For participant enrol biopsy cohort consent optional tumor biopsy , pretreatment tumor biopsy may use Inflammatory metaplastic breast cancer History leptomeningeal disease Type 1 2 diabetes require antihyperglycemic medication Inability unwillingness swallow pill Malabsorption syndrome condition would interfere enteral absorption Known untreated , active central nervous system metastasis Uncontrolled pleural effusion ascites Serious infection require antibiotic Concurrent ocular intraocular condition require medical surgical intervention prevent treat vision loss Active inflammatory infectious condition either eye history idiopathic autoimmuneassociated uveitis Daily supplemental oxygen History active inflammatory disease active bowel inflammation Symptomatic hypercalcemia require bisphosphonate denosumab therapy Significant traumatic injury major surgical procedure within 4 week prior start study treatment Clinically significant history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis Treatment chemotherapy , immunotherapy , biologic therapy anticancer therapy within 3 week , treatment endocrine therapy kinase inhibitor within 2 week , prior start study treatment , except premenopausal participant breast cancer may continue Gonadotropinreleasing hormone agonist therapy Radiation therapy cancer therapy within 4 week , palliative radiation bony metastasis within 2 week , prior start study treatment History malignancy within 5 year , except treat carcinoma situ cervix , nonmelanoma skin carcinoma , Stage I uterine cancer History active ventricular dysrhythmias congestive heart failure require medication symptomatic coronary heart disease Congenital long QT syndrome , prolong QT interval , family history sudden unexplained death long QT syndrome Current treatment medication know prolong QT interval Stage I : History significant toxicity relate another phosphatidylinositol 3kinase ( PI3K ) inhibitor mammalian target rapamycin ( mTOR ) inhibitor require treatment discontinuation Stage I Arm A : Pregnancy , lactation , intention become pregnant father child study Stage I Arm B : history significant toxicity relate cyclindependent kinase ( CDK ) 4/6 inhibitor , bone marrow transplant extensive radiotherapy ≥25 percent ( % ) bone marrow Stage II : Prior treatment &gt; 1 chemotherapy regimen metastatic disease Prior treatment PI3K inhibitor History significant toxicity relate mTOR inhibitor require treatment discontinuation Stage II Arm B : prior CDK4/6 inhibitor treatment , bone marrow transplant extensive radiotherapy ≥25 % bone marrow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>